Roche has shared that the US Food and Drug Administration (FDA) has granted De Novo authorisation for the cobas pro i 601 platform with the Ionify Gabapentin assay, components of its cobas Mass Spec solution.
Designed to bring advanced mass spectrometry testing into routine clinical laboratories, the solution combines the analytical capabilities of mass spectrometry with an automated, standardised workflow, expanding Roche’s diagnostic menu into therapeutic drug monitoring.
Mass spectrometry can be used for clinical applications that require highly sensitive and specific measurement, but traditional methods often involve specialised personnel and complex manual workflows. Roche is supporting the transition of mass spectrometry from specialised reference facilities to the core laboratory, turning complex testing into an accessible, standardised solution for routine clinical practice.
Authorised through the De Novo pathway, the Ionify Gabapentin assay adds a therapeutic drug monitoring application to a U.S. menu that includes 25-Hydroxy Vitamin D total and steroid hormone testing assays. Roche continues to develop additional clinical mass spectrometry assays to broaden the menu over time. Demonstrating an innovative, collaborative approach with the FDA, Roche will leverage a Predetermined Change Control Plan (PCCP) to accelerate future clinical mass spectrometry menu expansion while still maintaining rigorous safety and quality standards. The authorised PCCP includes expanding up to 22 Ionify assays on the cobas pro i 601 platform as PCCP requirements are met.
Dan Malarek, president and CEO of Roche Diagnostics North America, said, “Some of the best diagnostic technologies are often very complex and, in the end, don’t actually reach patients. Mass spectrometry has long been valued for its analytical performance, but the complexity of traditional workflows has limited its use in routine laboratories. By automating and standardising this technology, we’re helping make sophisticated testing more accessible to laboratories, clinicians and patients who depend on reliable results.”